Entry Point Capital, LLC Ionis Pharmaceuticals Inc Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding IONS
# of Institutions
394Shares Held
125MCall Options Held
2.25MPut Options Held
510K-
Vanguard Group Inc Valley Forge, PA13.8MShares$649 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD12.6MShares$593 Million0.38% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$484 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.26MShares$387 Million6.59% of portfolio
-
Wellington Management Group LLP Boston, MA6.57MShares$308 Million0.06% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $6.66B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...